FA
LAB icon

Friess Associates’s Standard BioTools LAB Stock Holding History

Friess Associates’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-193,100
Closed -$2.38M – 121
2019
Q2 		$2.38M Buy
+193,100
New +$2.46M 0.17% 99
2014
Q2 		– Sell
-17,530
Closed -$773K – 154
2014
Q1 		$773K Sell
17,530
-219,928
-93% -$9.68M 0.06% 76
2013
Q4 		$9.09M Buy
237,458
+206,458
+666% +$6.08M 0.68% 56
2013
Q3 		$680K Buy
+31,000
New +$609K 0.05% 73

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Friess Associates's LAB Position: Q3 2019 in Review

Friess Associates sold out of Standard BioTools (LAB) in Q3 2019, closing a stake of 193,100 shares — an estimated $2.38M sold.

Friess Associates first reported a position in LAB in Q3 2013 and held it in 4 quarters. The position peaked at $9.09M in Q4 2013. 125 funds tracked by Wall St. Rank hold LAB as of Q3 2019.

  • Friess Associates reported no remaining Standard BioTools position as of Q3 2019 after selling out during the quarter.
  • Friess Associates sold 193,100 Standard BioTools shares in Q3 2019, an estimated $2.38M.
  • Friess Associates first reported a position in Standard BioTools in Q3 2013 and held it in 4 quarters.
  • Friess Associates's Standard BioTools position peaked at $9.09M in Q4 2013.
  • 125 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2019.

Based on Friess Associates's 13F filing for Q3 2019, filed 14 Nov 2019.